ALKS Alkermes Plc

ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc

NEW YORK--(BUSINESS WIRE)--

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Alkermes plc (“Alkermes” or the “Company”) (NASDAQ: ALKS) violated federal securities laws.

Click here to learn about the case: http://docs.wongesq.com/ALKS-Info-Request-Form-1744. There is no cost or obligation to you.

On November 6, 2017, it was announced that an investigation has commenced concerning Alkermes’ sales practices for Vivitrol. In particular, Senator Kamala Harris said the Company had “aggressively marketed” Vivitrol and contributed to “misconceptions about other medications used in the fight to combat the opioid epidemic...”

To learn more about the investigation of Alkermes contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/ALKS-Info-Request-Form-1744.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
30/11/2017

Underlying

ALKSAlkermes Plc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alkermes Plc

EUR 152.32
ALKS ALKERMES PLC

Alkermes, Inc.: Credit analysis following assignment of Ba2 CFR

Our credit view of this issuer reflects its strong credit metrics highlighted by moderate financial leverage, constrained by its pipeline execution and commercialization risk.

01/22/26 January 22, 2026 1 EN
EUR 152.32
ALKS ALKERMES PLC

Moody's Ratings assigns Ba2 CFR to Alkermes; outlook stable

Moody's Ratings  (Moody's) assigned ratings to Alkermes, Inc. ("Alkermes"), including a Ba2 Corporate Family Rating (CFR), Ba2-PD Probability of Default Rating (PDR). Concurrently, we assigned Ba2 ratings to the senior secured bank credit facilities comprised of term loan A due 2031 and term loan B ...

01/20/26 January 20, 2026 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.31
AMN AMN Healthcare ...
XEL Xcel Energy Inc... ... (+29)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

AMN AMN HEALTHCARE SERVICES INC.
XEL XCEL ENERGY INC.
SGRY SURGERY PARTNERS INC.
SGMO SANGAMO THERAPEUTICS INC.
PLOW DOUGLAS DYNAMICS INC.
NWL NEWELL BRANDS INC
MCD MCDONALD'S CORPORATION
LAD LITHIA MOTORS INC. CLASS A
HAS HASBRO INC.
GTY GETTY REALTY CORP.
CLX CLOROX COMPANY
APD AIR PRODUCTS AND CHEMICALS INC.
ANGO ANGIODYNAMICS INC.
ALKS ALKERMES PLC
LBRDA LIBERTY BROADBAND CORP. CLASS A
MAT MATTEL INC.
UHT UNIVERSAL HEALTH REALTY INCOME TRUST
VFC V.F. CORPORATION
FLGT FULGENT GENETICS
PFE PFIZER INC.
CWEN CLEARWAY ENERGY INC. CLASS C
PEAK HEALTHPEAK PROPERTIES INC.
LSTR ELECTROSTAR S.A.
MTCH MATCH GROUP INC.
HRMY HARMONY BIOSCIENCES HOLDINGS
BALY BALLYS CORPORATION
SHYF THE SHYFT GROUP INC
NWM NORWEST MINERALS
DOUG DOUGLAS ELLIMAN INC
08/08/24 August 8, 2024 1 EN
EUR 211.55
ALKS ALKERMES PLC

Alkermes, Inc.: Update to credit analysis

Alkermes credit profile reflects its modest financial leverage and strong liquidity, offset by revenue concentration in three neuroscience-based products and approaching generic competition.

03/04/24 March 4, 2024 1 EN
EUR 152.32
ALKS ALKERMES PLC

Moody's affirms Alkermes' Ba3 CFR, outlook stable

Moody's Investors Service ("Moody's") affirmed the ratings of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes"). The affirmed ratings include the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, and the Ba3 senior secured term loan rating. There is no chang...

02/28/24 February 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch